Scholarlink

<p>Tear fluid is a promising source of biomarkers for Alzheimer’s disease (AD). This study characterized the tear fluid proteome across AD and dementia stages. Tear fluid was collected from 60 participants, cognitively normal (CN) individuals (<i>n</i> = 32), patients with mild cognitive impairment (<i>n</i> = 14), and dementia (<i>n</i> = 14). Of these, 27 were amyloid PET-negative and 33 PET-positive. The proteome was analyzed using label-free mass spectrometry, followed by targeted validation immunoassays of key findings. In total, 703 proteins were reliably identified. A notable upregulated protein in dementia compared with CN was glutathione synthetase (GSS) (1.7-fold, <i>p</i> = 0.02). Validation revealed elevated GSS (2-fold) and its enzymatic product glutathione (1.7-fold) in tear fluid of amyloid PET–positive participants. Incorporating GSS and glutathione as pre-screeners could reduce the need for PET scans by up to 75%. Tear fluid shows promise as a non-invasive source for AD biomarkers, offering novel disease insights, and potential utility for pre-screening prior to PET imaging.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of tear fluid glutathione synthetase and glutathione levels with amyloid positivity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月2日

查看全文
  • Nienke van de Sande,
  • Saleh Ahmed,
  • Ward van Deuse,
  • Willemijn J. Jansen,
  • Anouk den Braber,
  • Pieter Jelle Visser,
  • Frans R. J. Verhey,
  • Michelle Thach,
  • Frank D. Verbraak,
  • Femke H. Bouwman,
  • Rudy M.M.A. Nuijts,
  • Inez H. G. B. Ramakers,
  • Carroll A. B. Webers,
  • Ashok Sharma,
  • Marlies Gijs

摘要

Tear fluid is a promising source of biomarkers for Alzheimer’s disease (AD). This study characterized the tear fluid proteome across AD and dementia stages. Tear fluid was collected from 60 participants, cognitively normal (CN) individuals (n = 32), patients with mild cognitive impairment (n = 14), and dementia (n = 14). Of these, 27 were amyloid PET-negative and 33 PET-positive. The proteome was analyzed using label-free mass spectrometry, followed by targeted validation immunoassays of key findings. In total, 703 proteins were reliably identified. A notable upregulated protein in dementia compared with CN was glutathione synthetase (GSS) (1.7-fold, p = 0.02). Validation revealed elevated GSS (2-fold) and its enzymatic product glutathione (1.7-fold) in tear fluid of amyloid PET–positive participants. Incorporating GSS and glutathione as pre-screeners could reduce the need for PET scans by up to 75%. Tear fluid shows promise as a non-invasive source for AD biomarkers, offering novel disease insights, and potential utility for pre-screening prior to PET imaging.